The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter …

Background There are limited long-term outcome data in eculizumab-treated patients with
atypical hemolytic uremic syndrome (aHUS). We report final results from the largest …

Background Atypical hemolytic uremic syndrome (aHUS) is a devastating form of renal
thrombotic microangiopathy. Despite plasma exchange, the standard treatment of aHUS for …

Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …

With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for
patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very …

Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …

Introduction Eculizumab has transformed outcomes for patients with atypical hemolytic
uremic syndrome (aHUS). Its efficacy and safety profile was well characterized in the clinical …

Atypical hemolytic uremic syndrome (aHUS) is a rare, chronic, life-threatening disease due
to complement dysregulation. The use of early-onset plasma therapy is recommended, but …

Atypical hemolytic uremic syndrome (aHUS) in childhood is a rare disease associated with
high morbidity and mortality. Most cases progress to end-stage renal failure. In …

Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease
characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) …